Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1999 1
2000 6
2001 24
2002 34
2003 38
2004 30
2005 47
2006 58
2007 54
2008 55
2009 82
2010 100
2011 143
2012 152
2013 164
2014 228
2015 260
2016 291
2017 277
2018 271
2019 152
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

2,191 results
Results by year
Filters applied: . Clear all
Page 1
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu and Cancer Genome Atlas Research Network . Cancer Cell 2017. PMID 28810144 Free PMC article.
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low neoplastic cellularity. ...
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma (PDAC) specim …
Genetics and biology of pancreatic ductal adenocarcinoma.
Ying H, et al. Genes Dev 2016 - Review. PMID 26883357 Free PMC article.
With 5-year survival rates remaining constant at 6% and rising incidences associated with an epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PDAC) is on track to become the second most common cause of cancer-related deaths by 2030. ...
With 5-year survival rates remaining constant at 6% and rising incidences associated with an epidemic in obesity and metabolic syndrome, …
Genetics and biology of pancreatic ductal adenocarcinoma.
Hezel AF, et al. Genes Dev 2006 - Review. PMID 16702400 Free article.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States with a median survival of <6 mo and a dismal 5-yr survival rate of 3%-5%. ...Recent advances include insights into the cancer's cellular origins, high-resolution genomic profiles pointing to potential new therapeutic targets, and refined mouse models reflecting both the genetics and histopathologic evolution of human PDAC. ...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States with a median surviva
Pancreatic cancer.
Vincent A, et al. Lancet 2011 - Review. PMID 21620466 Free PMC article.
Furthermore, pancreatic cancer responds poorly to most chemotherapeutic agents. Hence, we need to understand the biological mechanisms that contribute to development and progression of pancreatic tumours. In this Seminar we will discuss the most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinoma....
Furthermore, pancreatic cancer responds poorly to most chemotherapeutic agents. Hence, we need to understand the biological mechanism …
Pancreatic Ductal Adenocarcinoma and Its Variants.
Luchini C, et al. Surg Pathol Clin 2016 - Review. PMID 27926359
The most common tumor type among pancreatic cancers is pancreatic ductal adenocarcinoma, an infiltrating neoplasm with glandular differentiation that is derived from pancreatic ductal tree. ...Furthermore, we present the classic features of the most common variants of pancreatic ductal adenocarcinoma. Last, we summarize the prognostic landscape of this highly malignant tumor and its variants....
The most common tumor type among pancreatic cancers is pancreatic ductal adenocarcinoma, an infiltrating neoplasm with …
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
Waters AM and Der CJ. Cold Spring Harb Perspect Med 2018 - Review. PMID 29229669 Free PMC article.
With the highest RAS mutation frequencies seen with the top three causes of cancer deaths in the United States (lung, colorectal, and pancreatic cancer), the development of anti-RAS therapies is a major priority for cancer research. ...With a near 100% KRAS mutation frequency, pancreatic ductal adenocarcinoma (PDAC) is considered the most RAS-addicted of all cancers. ...
With the highest RAS mutation frequencies seen with the top three causes of cancer deaths in the United States (lung, colorectal, and pan
Organoid models for translational pancreatic cancer research.
Tiriac H, et al. Curr Opin Genet Dev 2019 - Review. PMID 30844513 Free PMC article.
Despite recent advances in the treatment of cancer, pancreatic ductal adenocarcinoma (PDAC) still retains the worst survival rate of common malignancies. ...Pancreatic ductal organoids are ex-vivo models of PDAC that can be established from very small biopsies, enabling the study of localized, advanced, and metastatic patients. ...
Despite recent advances in the treatment of cancer, pancreatic ductal adenocarcinoma (PDAC) still retains the worst survival r …
Emerging strategies in BRCA-positive pancreatic cancer.
Kowalewski A, et al. J Cancer Res Clin Oncol 2018 - Review. PMID 29777302 Free PMC article.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest diseases in the United States and Europe. BRCA1 and BRCA2 are among the most common of the known genetic mutations involved in familial PDAC. ...METHODS: We conducted a review of the literature for data on possible therapies in BRCA-positive and BRCA-negative pancreatic cancer. ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest diseases in the United States and Europe. BRCA1 and BRCA2 are
Molecular subtypes of pancreatic cancer.
Collisson EA, et al. Nat Rev Gastroenterol Hepatol 2019 - Review. PMID 30718832
Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. ...
Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, s …
Genetics of Familial and Sporadic Pancreatic Cancer.
Wood LD, et al. Gastroenterology 2019 - Review. PMID 30660730
Whole-exome and whole-genome sequencing of pancreatic ductal adenocarcinomas have confirmed the critical driver genes altered in the majority of pancreatic cancers, as well as identified numerous less frequently altered driver genes, and have delineated cancer subgroups with unique biological and clinical features. ...In this review, we discuss the results of comprehensive genomic characterization of pancreatic ductal adenocarcinoma and its precursor lesions, and we highlight translational applications in early detection and therapy....
Whole-exome and whole-genome sequencing of pancreatic ductal adenocarcinomas have confirmed the critical driver genes altered …
2,191 results
Jump to page
Feedback